Revenue
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
CytomX Therapeutics, Inc. (CTMX)
Price$3.62Cached quote
Net income
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $76.2M | $138.1M | $101.2M | $53.2M | $37.3M | $68.4M | $26.9M | $59.5M | $71.6M | $12.8M | $7.7M | $5.1M | $888,000 |
| Research & development | $68.7M | $83.4M | $77.7M | $111.6M | $114.2M | $112.9M | $131.6M | $103.9M | $92.3M | $54.8M | $28.4M | $28.3M | $10.9M |
| Operating expenses | $98.6M | $113.1M | $107.7M | $154.5M | $153.4M | $149.0M | $168.4M | $137.4M | $117.9M | $74.6M | $40.9M | $34.8M | $15.8M |
| Operating income | −$22.4M | $25.0M | −$6.5M | −$101.3M | −$116.0M | −$80.5M | −$141.5M | −$77.9M | −$46.3M | −$59.6M | −$33.2M | −$29.8M | −$15.0M |
| Operating margin | −29.35% | 18.10% | −6.41% | −190.61% | −311.00% | −117.70% | −525.92% | −130.88% | −64.59% | −463.88% | −430.54% | −586.27% | −1,684.23% |
| EBITDA | −$21.0M | $26.7M | −$4.3M | −$98.9M | −$113.3M | −$78.0M | −$138.8M | −$76.0M | −$44.6M | −$57.9M | −$32.0M | −$29.0M | −$14.3M |
| EBITDA margin | −27.58% | 19.36% | −4.29% | −186.01% | −303.64% | −113.98% | −516.08% | −127.71% | −62.29% | −450.39% | −414.90% | −570.85% | −1,610.47% |
| Net income | −$17.4M | $31.9M | −$569,000 | −$99.3M | −$115.9M | −$64.8M | −$132.8M | −$84.6M | −$43.1M | −$58.9M | −$35.4M | −$30.3M | −$15.1M |
| Net profit margin | −22.79% | 23.08% | −0.56% | −186.82% | −310.54% | −94.73% | −493.74% | −142.19% | −60.17% | −458.54% | −458.69% | −597.01% | −1,705.29% |
| Basic EPSper basic share | -$0.15 | $0.38 | -$0.01 | -$1.51 | — | — | — | — | -$1.16 | -$1.63 | -$4.90 | -$35.25 | -$24.46 |
| Diluted EPSper diluted share | -$0.15 | $0.38 | -$0.01 | -$1.51 | — | — | — | — | -$1.16 | -$1.63 | -$4.90 | -$35.25 | -$24.46 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
FMR LLC | 32.71M |
Kynam Capital Management, LP | 21.7M |
BlackRock, Inc. | 17.56M |
BANK OF AMERICA CORP /DE/ | 15.08M |
STATE STREET CORP | 11.75M |
PERCEPTIVE ADVISORS LLC | 10.44M |
VANGUARD CAPITAL MANAGEMENT LLC | 8.53M |
Point72 Asset Management, L.P. | 7.81M |
WELLINGTON MANAGEMENT GROUP LLP | 5.17M |
Venrock Adviser, LLC | 4.98M |
BAKER BROS. ADVISORS LP | 4.98M |
GEODE CAPITAL MANAGEMENT, LLC | 4.68M |
Elmind Capital, LP | 4.55M |
Nextech Invest Ltd. | 4.45M |
TWO SIGMA INVESTMENTS, LP | 4.13M |
Eversept Partners, LP | 3.56M |
UBS Group AG | 3.47M |
Siren, L.L.C. | 3.46M |
ADAR1 Capital Management, LLC | 3.37M |
CITADEL ADVISORS LLC | 3.11M |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 15, 2026Form 4 | Ogden ChristopherChief Financial Officer | SellCommon Stock | 1.6K | $3.05 | $5.0K | 295.3K |
| Mar 17, 2026Form 4 | Chu Yu-WayeChief Medical Officer | SellCommon Stock | 21.3K | $6.42 | $136.6K | 189.4K |
| Mar 17, 2026Form 4 · 10b5-1 | McCarthy Sean A.CEO | SellCommon Stock | 119.0K | $6.42 | $763.8K | 1.08M |
| Mar 17, 2026Form 4 | BELVIN MARCIASVP, Chief Scientific Officer | SellCommon Stock | 31.5K | $6.42 | $202.2K | 300.8K |
| Mar 17, 2026Form 4 | Ogden ChristopherChief Financial Officer | SellCommon Stock | 19.3K | $6.42 | $124.1K | 296.9K |